Upstream Bio (NASDAQ:UPB) Sees Large Volume Increase - Here's What Happened

Key Points

• Upstream Bio's stock experienced a trading volume of 352,890 shares, nearly matching the previous day's volume, with the stock price rising from $17.13 to $17.97.
• Analysts have upgraded Upstream Bio from a "sell" to a "hold" rating, with a consensus rating of "Buy" and a target price of $56.50.
• The company recently reported a quarterly loss of ($0.74) per share, which was lower than the expected loss of ($0.61), and had a revenue of $0.94 million against a consensus estimate of $0.32 million.

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 352,890 shares were traded during mid-day trading, a decline of 0% from the previous session's volume of 354,177 shares.The stock last traded at $17.97 and had previously closed at $17.13.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Upstream Bio from a "sell" rating to a "hold" rating in a research report on Friday, June 6th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $56.50.

Upstream Bio Stock Up 1.5%

The stock has a fifty day moving average of $14.80 and a 200-day moving average of $10.88.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.13). Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%.The company had revenue of $0.94 million during the quarter, compared to analysts' expectations of $0.32 million. Analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in Upstream Bio during the 4th quarter valued at $25,000. Tower Research Capital LLC TRC acquired a new stake in Upstream Bio in the fourth quarter worth $47,000. Legal & General Group Plc lifted its stake in Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company's stock valued at $35,000 after acquiring an additional 1,440 shares in the last quarter. CWM LLC grew its stake in Upstream Bio by 107.5% in the second quarter. CWM LLC now owns 3,312 shares of the company's stock valued at $36,000 after purchasing an additional 1,716 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in shares of Upstream Bio by 95.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company's stock valued at $39,000 after acquiring an additional 1,736 shares during the period.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.